Showing 3961-3970 of 9345 results for "".
- WCD News: Experts Excited About Ornovi’s Next Generation JAK Inhibitorhttps://practicaldermatology.com/news/wcd-news-experts-excited-about-ornovis-next-generation-jak-inhibitor/2461833/Ornovi's OR-101 is a highly selective next generation JAK3-ITK inhibitor with potentially a better safety profile than JAK inhibitors currently on the market, according to a presentation at the 25th World Congress of Dermatology Meeting 2023 in Singapore. Seemal Desa
- Merz Aesthetics to Distribute AccuVein’s Visualization Systemhttps://practicaldermatology.com/news/merz-aesthetics-to-distribute-accuveins-visualization-system/2461829/Merz Aesthetics is now the sole authorized distributor of AccuVein’s vein visualization system in the U.S. aesthetics market. A limited initial AccuVein field pilot yielded positive results and significant expansion of both new customers and Merz Aesthetics portfolio adoption. Bas
- Merz Aesthetics Taps Christina Aguilera as New Xeomin Brand Partnerhttps://practicaldermatology.com/news/merz-aesthetics-taps-christina-aguilera-as-new-xeomin-brand-partner/2461588/Christina Aguilera is the latest Xeomin (incobotulinumtoxinA) brand partner as Merz Aesthetics expands its ‘Beauty on Your Terms’ marketing campaign. Launched in August 2022, the campaign features multiple music icons in support of Xeomin.
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no
- Coming Soon? The first FDA-approved Topical Prescription Product for Molluscumhttps://practicaldermatology.com/news/coming-soon-the-first-fda-approved-topical-prescription-product-for-molluscum/2461485/Ligand Pharmaceuticals Inc.’s partner Novan submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical treatment of molluscum contagiosum. Assuming the filing is accepted b
- Leo Pharma's Adtralza Gets Nod or Adults with AD in Japanhttps://practicaldermatology.com/news/leo-pharmas-adtralza-gets-nod-or-adults-with-ad-in-japan/2461476/The Japan Ministry of Health, Labor and Welfare has granted approval for the manufacturing and marketing of LEO Pharma’s Adtralza (tralokinumab) subcutaneous injection for adults with atopic dermatitis, which has inadequately responded to conventional therapies. “Today&
- DermTech, Sonora Quest Laboratories Join Forces Expand Access to Melanoma Detection Test in Arizonahttps://practicaldermatology.com/news/dermtech-sonora-quest-laboratories-join-forces-expand-access-to-melanoma-detection-test-in-arizona/2461434/Sonora Quest is the exclusive laboratory offering the DermTech Melanoma Test for all of Arizona. The DermTech Melanoma Test uses a non-invasive Smart Sticker to lift skin cells from the surface of a patient’s skin to be tested for select genomic markers associated with melanoma. I
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod
- European Commission Approves LEO Pharma’s Adtralza (tralokinumab) for the Treatment of Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/european-commission-approves-leo-pharmas-adtralza-tralokinumab-for-the-treatment-of-moderate-to-severe-ad-in-adolescents/2461394/The European Commission (EC)e xtended the marketing authorization for LEO Pharma’s Adtralz (tralokinumab) to include adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. “Safety is a priority when s
- Apyx Medical Corporation Receives FDA 510(k) Clearance for Renuvion Handpiecehttps://practicaldermatology.com/news/apyx-medical-corporation-receives-fda-510k-clearance-for-renuvion-handpiece/2461216/The U.S. Food and Drug Administration has granted marketing clearance to Apyx Medical Corporation’s Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures for the treatment of moderate to